Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Editas Medicine (EDIT) EBIT Margin: 2015-2025

Historic EBIT Margin for Editas Medicine (EDIT) over the last 10 years, with Sep 2025 value amounting to -325.44%.

  • Editas Medicine's EBIT Margin rose 10732374.00% to -325.44% in Q3 2025 from the same period last year, while for Sep 2025 it was -428.71%, marking a year-over-year decrease of 5868.00%. This contributed to the annual value of -777.22% for FY2024, which is 56067.00% down from last year.
  • Editas Medicine's EBIT Margin amounted to -325.44% in Q3 2025, which was up 77.41% from -1,440.58% recorded in Q2 2025.
  • Editas Medicine's EBIT Margin's 5-year high stood at -39.90% during Q4 2023, with a 5-year trough of -136,952.38% in Q3 2022.
  • In the last 3 years, Editas Medicine's EBIT Margin had a median value of -1,440.58% in 2025 and averaged -12,195.06%.
  • As far as peak fluctuations go, Editas Medicine's EBIT Margin tumbled by 13,631,896bps in 2022, and later soared by 13,601,229bps in 2023.
  • Quarterly analysis of 5 years shows Editas Medicine's EBIT Margin stood at -333.71% in 2021, then crashed by 63,701bps to -970.72% in 2022, then skyrocketed by 93,081bps to -39.90% in 2023, then tumbled by 11,234bps to -152.24% in 2024, then surged by 10,732,374bps to -325.44% in 2025.
  • Its last three reported values are -325.44% in Q3 2025, -1,440.58% for Q2 2025, and -1,635.10% during Q1 2025.